A Long-Term Follow-Up Study of Participants Exposed to REACT

Recruiting now

Conditions studied: Diabetic Kidney Disease, Chronic Kidney Diseases

In brief

The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).

Key facts

Study ID

NCT05918523

Run by

Prokidney

People needed

80

Starts

2023-12-11

Expected to finish

2028-03-01

Last updated by the study team

2025-05-28

Who can join

Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The participant must have received gelatin-hydrogel formulation REACT in a previous trial (RMCL-002, REGEN-003, REGEN-004) for the treatment of chronic kidney disease and completed an end of study visit in their parent trial per protocol.

You may not qualify if…

• The participant did not receive REACT in a previous trial for the treatment of chronic kidney disease.

Where it is running

• Boise Kidney & Hypertension Institute — Meridian, Idaho, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.